Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 173 participants.

Also called NCT04069078

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 173 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04069078
Other papers using this trial's data
  • Hemodynamic and antiemetic effects of prophylactic hyoscine butyl-bromide during cesarean section under spinal anesthesia: a randomized controlled trial BMC anesthesiology, 2022-04-21 DOI, PubMed 35448942, PMC9027476 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04069078. Randomized; triple masking; primary purpose prevention. Start 2019-10-10 (actual); primary completion 2020-02-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section
Condition
Bradycardia
Condition
Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
Condition
Cesarean Section Complications
Intervention (Drug)
Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule
Intervention (Other)
Normal saline
Lead sponsor
Assiut University (class: other)

Record details

Record id
cardio:ct-nct04069078
Content hash
da3c1c5d99f1e3b2656c5eae0b5a18843fc4c1ad2d16d53584f4282ea1153aef